RUBY Rubius Therapeutics Inc

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

$12.33  +0.26 (2.15%)
As of 12/06/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/18/2018
Outstanding shares:  89,865,777
Average volume:  383,322
Market cap:   $1,084,679,928
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    78116T103
ISIN:        US78116T1034
Sedol:      BDD1B07
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.94
PS ratio:   0.00
Return on equity:   -81.20%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy